CASI Pharmaceuticals Inc. has announced results from its Phase 1 open-label study of CID-103, an anti-CD38 monoclonal antibody, in adult patients with immune thrombocytopenia $(ITP)$. The data were presented at the 67th American Society of Hematology Annual Meeting and Exposition on December 7, 2025, in Orlando, Florida. The study, conducted under an FDA-approved Investigational New Drug application and a Clinical Trial Application approved by the Chinese Center for Drug Evaluation, incorporates multiple adaptive design elements, including intra-patient dose escalation and dose expansion as determined by a Safety Monitoring Committee. CID-103 is being developed for the treatment of organ transplant rejection and autoimmune diseases.